Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Beginning Cash Balance (2023)

Historic Beginning Cash Balance for C4 Therapeutics (CCCC) over the last 1 years, with Q3 2023 value amounting to $11.0 million.

  • C4 Therapeutics' Beginning Cash Balance changed N/A to $11.0 million in Q3 2023 from the same period last year, while for Jun 2024 it was $11.0 million, marking a year-over-year increase of 63333.33%. This contributed to the annual value of $12.5 million for FY2023, which is N/A changed from last year.
  • Per C4 Therapeutics' latest filing, its Beginning Cash Balance stood at $11.0 million for Q3 2023.
  • Over the past 5 years, C4 Therapeutics' Beginning Cash Balance peaked at $11.0 million during Q3 2023, and registered a low of $750000.0 during Q1 2023.